[Reduction of gastric acid secretion: pathophysiologic and clinically relevant sequelae].
After proton pump inhibitors (omeprazole) became available, discussions about safety aspects of (particularly long-term) inhibition of gastric acid secretion have been renewed. In contrast to animals, hypergastrinaemia does not seem to be a relevant problem in man: marginal increases of serum gastrin during proton pump inhibition may induce proliferation of gastric endocrine ("enterochromaffin-like"; ECL-) cells in some cases which are without clinical importance, the risk for development of gastric carcinoids seems negligible if existent at all. Other aspects of acid inhibition (e.g. protein malabsorption, diminished iron and cobalamin absorption, bacterial overgrowth of the stomach, risk of gastric cancer) do also not appear to be of clinical relevance. However, data from larger numbers of patients on long-term therapy with proton pump inhibitors should be available until such treatment can be generally recommended.
Abteilung für Gastroenterologie und Stoffwechsel, Philipps-Universität Marburg, Bundesrepublik Deutschland.
H
H
Koop
R
R
Eissele
D000818:Animals; D005745:Gastric Acidity Determination; D006635:Histamine H2 Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009853:Omeprazole / Q000009:adverse effects* / Q000627:therapeutic use
D006635:Histamine H2 Antagonists; D009853:Omeprazole
Gastrale Säurereduktion: Pathophysiologische und klinisch relevante Folgen.